## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.27 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates). Caution: declining volume (32% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($455.28)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. HCA Healthcare (HCA) Stock After Hours on Dec. 24, 2025: What Happened After the Bell and What to Know Before Markets Reopen**
- Source: ts2.tech | 20251225T045422 | Neutral | Relevance: 100%
- HCA Healthcare (HCA) stock closed essentially flat on Christmas Eve, December 24, 2025, but saw a slight after-hours dip of about 1.12% to $468.74, largely attributed to thin holiday trading liquidity and broader healthcare sector sentiment rather than company-specific news. Investors are now looking to Friday, December 26, as markets were closed for Christmas Day, with key factors including policy uncertainty around ACA premium subsidies and upcoming Q4 earnings estimates. The article also touches on institutional ownership shifts, local expansion chatter, updated 2025 guidance, and analyst forecasts for HCA heading into the new year.

**2. Valley National Advisers Inc. Increases Stock Position in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251228T130743 | Bullish | Relevance: 100%
- Valley National Advisers Inc. significantly increased its stake in HCA Healthcare (NYSE:HCA) by 6,457.5% in the third quarter, bringing its total to 4,787 shares valued at $2.04 million. Other institutional investors like Norges Bank, Pacer Advisors, and Viking Global also made substantial investments, pushing institutional ownership to 62.73%. HCA Healthcare reported strong Q3 earnings, beating estimates with $6.96 EPS and $19.16 billion revenue, and maintains a "Moderate Buy" consensus rating with an average price target of $479.00.

**3. Greenup Street Wealth Management LLC Grows Holdings in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251227T115749 | Bullish | Relevance: 100%
- Greenup Street Wealth Management LLC significantly increased its stake in HCA Healthcare by 40.7% in Q3, now owning 8,767 shares worth approximately $3.737 million. This move is part of broader institutional interest in HCA, with hedge funds and other investors collectively holding about 62.73% of the company's stock. HCA Healthcare recently surpassed Q3 earnings and revenue estimates and holds a "Moderate Buy" consensus analyst rating.

**4. Highland Capital Management LLC Buys Shares of 3,789 HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251227T114949 | Somewhat-Bullish | Relevance: 100%
- Highland Capital Management LLC has acquired 3,789 shares of HCA Healthcare, Inc. (NYSE:HCA) valued at approximately $1.615 million during the third quarter. This comes amidst other institutional investor activities and an insider sale by EVP Michael R. McAlevey. HCA Healthcare also reported strong Q3 earnings, exceeding expectations, and announced a quarterly dividend.

**5. HCA Healthcare, Inc. $HCA Shares Sold by Burney Co.**
- Source: MarketBeat | 20251227T093500 | Somewhat-Bullish | Relevance: 100%
- Burney Co. significantly reduced its stake in HCA Healthcare by 12% in Q3, selling 3,907 shares and retaining 28,542 shares valued at $12.17 million. Institutional investors collectively own 62.73% of the company, which recently reported strong quarterly results with $6.96 EPS and $19.16 billion in revenue, exceeding analyst estimates. HCA Healthcare also announced a quarterly dividend of $0.72 and has a "Moderate Buy" consensus rating from analysts with a target price of $479.00.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $520 | $505 | +3% |
| 2025-12-15 | Morgan Stanley | $425 | $425 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Outperform |
| 2025-12-15 | Morgan Stanley | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.27 suggests fair value with growth premium. Forward P/E 16.1x stretched relative to 7% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $111.6B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.27 |
| Forward P/E | 16.1 |
| Current P/E | 17.2 |
| YoY Growth | 7.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -3.3% to -1.8% (+1.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.8pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.20x) but short-term weakness (below SMA20). MACD histogram bearish (-1.79), momentum weakening. RSI neutral at 50. Volume at 32% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.80% (CS: 28) | Neutral |
| RSI_14 | 50.2 | Neutral |
| MACD Histogram | -1.79 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 1.009x | Above |
| vs SMA200 | 1.196x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $477.22
- **Stop Loss:** $455.28 (4.6% risk)
- **Target:** $521.10 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 60
- **Position Value:** $28,633.20
- **Portfolio %:** 28.63%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*